Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.
BMI
liraglutide
obesity class
persistence
weight loss
Journal
Obesity science & practice
ISSN: 2055-2238
Titre abrégé: Obes Sci Pract
Pays: United States
ID NLM: 101675151
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
13
01
2020
revised:
03
04
2020
accepted:
05
04
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real-world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real-world clinical setting. Secondary analysis of an observational, retrospective study of liraglutide 3.0 mg for weight management (as adjunct to diet and exercise) at six Wharton Medical Clinics in Canada. Patients were categorized by body mass index (BMI, kg/m Of 308 patients, 70 (22.7%) had obesity class I, 83 (26.9%) obesity class II and 155 (50.3%) obesity class III. Similar percentage change in weight was observed between obesity classes (mean [standard deviation, SD]: -7.0% [6.0], -6.6% [6.0] and -6.1% [5.0], respectively; These findings suggest that real-world treatment with liraglutide 3.0 mg, regardless of obesity class, is associated with similar clinically significant weight loss, time to maintenance dose and medication persistence.
Identifiants
pubmed: 32874678
doi: 10.1002/osp4.420
pii: OSP4420
pmc: PMC7448201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
439-444Informations de copyright
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
S.W.: owner and medical director of the Wharton Medical Clinic (WMC) and internal medicine specialist at Hamilton Health Sciences. He has previously received funding in the forms of grants for research from CIHR and Mitacs and also received funding in the past from Novo Nordisk, Bausch Health, Eli Lilly, Janssen and AstraZeneca for advisory work.C.L.H.: employee of Novo Nordisk A/S, Copenhagen, Denmark.E.K.: research coordinator at WMC and a member of this working group.A.L.: employee of Novo Nordisk Canada Inc.J.M.: employee of IQVIA Solutions Canada Inc., responsible for the study (management, analysis and dissemination).D.N.: employee of IQVIA Solutions Canada Inc., responsible for the study (management, analysis and dissemination).A.P.: employee of Novo Nordisk A/S, Copenhagen, Denmark.G.S.P.: employee of IQVIA Solutions Canada Inc., responsible for the study (management, analysis and dissemination).R.A.G.C. was an employee of WMC at the time of this study and is a member of this working group.
Références
Am J Clin Nutr. 1992 Aug;56(2):320-8
pubmed: 1386186
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
pubmed: 24731674
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Diabetes Care. 2015 Aug;38(8):1567-82
pubmed: 26421334
Diabetes Care. 2011 Jul;34(7):1481-6
pubmed: 21593294
Obes Rev. 2014 Mar;15(3):169-82
pubmed: 24118750
Diabetes Obes Metab. 2019 Jun;21(6):1498-1501
pubmed: 30768836
Arch Intern Med. 2009 Sep 28;169(17):1619-26
pubmed: 19786682
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Obes Facts. 2017;10(6):531-544
pubmed: 29145215
Sleep. 2013 May 01;36(5):641-649A
pubmed: 23633746
Obesity (Silver Spring). 2019 Jun;27(6):917-924
pubmed: 31062937
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Int J Clin Pract. 2019 Nov;73(11):e13399
pubmed: 31397946